Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6483871 | 0.81 | CES2 (0.31) | CES2CES1 | |
| SCHEMBL1090760 | 0.81 | HDAC1 (0.33) | — | |
| SCHEMBL30502469 | 0.80 | CES2 (0.33) | CA2CES2CES1 | |
| SCHEMBL2993734 | 0.80 | CES2 (0.33) | CA2CES2CES1 | |
| SCHEMBL2557587 | 0.76 | ALDH1A1 (0.31) | CES2CES1 | |
| SCHEMBL29460057 | 0.76 | ALDH1A1 (0.31) | CES2CES1 | |
| SCHEMBL31285745 | 0.76 | — | — | |
| SCHEMBL28824845 | 0.73 | — | — | |
| SCHEMBL12433524 | 0.71 | RAPGEF4 (0.36) | CA2LPLLIPGCES2CES1 | |
| SCHEMBL29281141 | 0.71 | CA2 (0.37) | CA2LPLLIPGCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119285442-A | Method for synthesizing 2-methyl-3, 4, 5-trifluoro phenol | 石家庄市凯信电子材料有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-119285442-A | Method for synthesizing 2-methyl-3, 4, 5-trifluoro phenol | 石家庄市凯信电子材料有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119285442-A | Method for synthesizing 2-methyl-3, 4, 5-trifluoro phenol | 石家庄市凯信电子材料有限公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2019185025-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | 正大天晴药业集团股份有限公司 | 2019-10-03 | — | — | WO | disclosed |
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-12-18 | — | — | US | disclosed |
| US-8759334-B2 | Compounds useful for the treatment of metabolic and inflammatory diseases | GALAPAGOS NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-20130303515-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2013-11-14 | — | — | US | disclosed |
| US-7297799-B2 | Preparation of benzoylalkyl-1,2,3,6-tetrahydropyridines and use thereof | SANOFI-AVENTIS (FR) | 2007-11-20 | — | — | US | disclosed |
| US-20070054931-A1 | PREPARATION OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES AND USE THEREOF | SANOFI-AVENTIS (FR) | 2007-03-08 | — | — | US | disclosed |
| US-7151107-B2 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | SANOFI-AVENTIS (FR) | 2006-12-19 | — | — | US | disclosed |
| US-6890937-B2 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION (US) | 2005-05-10 | — | — | US | disclosed |
| US-6750233-B2 | SELECTIVITY | PHARMACIA CORPORATION | 2004-06-15 | — | — | US | disclosed |
| WO-2002083683-A9 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2004-02-26 | — | — | WO | disclosed |
| EP-1377586-A1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | disclosed |
| EP-1377581-A1 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | disclosed |
| EP-1377583-A1 | NOVEL TRICYCLIC HYDROXY CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | disclosed |
| US-6541489-B1 | Excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP- 1 | G. D. SEARLE & COMPANY | 2003-04-01 | — | — | US | disclosed |
| WO-2002083683-A1 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083680-A1 | NOVEL TRICYCLIC HYDROXY CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083678-A1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GOT2, GPR119, PC | CA2 4738/4885LPL 130/4885LIPG 49/4885 |
| US-20130303515-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GOT2, GPR119, PC | CA2 4738/4885LPL 130/4885LIPG 49/4885 |
| US-20070054931-A1 | PREPARATION OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES AND USE THEREOF | BDNF, KCNH1, GABRA6 | CA2 583/4885LPL 4412/4885LIPG 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.